UBS Resumes Regeneron Coverage at Buy, Citing Dupixent Follow-Ons

UBS resumed coverage of Regeneron Pharmaceuticals with a Buy rating, citing potential value from follow-on treatments to Dupixent and the possibility of expanding the drug’s exclusivity. Dupixent, also known as dupilumab, is Regeneron’s blockbuster treatment. UBS’s assessment is that the Street is not accounting for enough value from the drug’s follow-on development or its exclusivity potential. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Source: TokenPost